Hazem Elewa

1.7k total citations
80 papers, 1.3k citations indexed

About

Hazem Elewa is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Pharmacology. According to data from OpenAlex, Hazem Elewa has authored 80 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Cardiology and Cardiovascular Medicine, 23 papers in Internal Medicine and 21 papers in Pharmacology. Recurrent topics in Hazem Elewa's work include Atrial Fibrillation Management and Outcomes (32 papers), Venous Thromboembolism Diagnosis and Management (23 papers) and Pharmacogenetics and Drug Metabolism (18 papers). Hazem Elewa is often cited by papers focused on Atrial Fibrillation Management and Outcomes (32 papers), Venous Thromboembolism Diagnosis and Management (23 papers) and Pharmacogenetics and Drug Metabolism (18 papers). Hazem Elewa collaborates with scholars based in Qatar, United States and Egypt. Hazem Elewa's co-authors include Susan C. Fagan, Anna Kozak, Sandro Lemos Machado, Maribeth H. Johnson, Adviye Ergul, David C. Hess, Daoud Al‐Badriyeh, Kyle John Wilby, Azza B. El‐Remessy and Ahmed Awaisu and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Stroke.

In The Last Decade

Hazem Elewa

74 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hazem Elewa Qatar 22 368 231 205 202 201 80 1.3k
Michael J. Fossler United States 22 230 0.6× 105 0.5× 21 0.1× 371 1.8× 100 0.5× 69 1.5k
Célia Maria Cássaro Strunz Brazil 21 552 1.5× 197 0.9× 35 0.2× 191 0.9× 52 0.3× 91 1.5k
Joshua Goldberg United States 22 271 0.7× 232 1.0× 98 0.5× 380 1.9× 9 0.0× 72 1.4k
Zhi Liu China 20 228 0.6× 175 0.8× 37 0.2× 228 1.1× 61 0.3× 70 1.4k
Shashank Rohatagi United States 27 706 1.9× 57 0.2× 22 0.1× 202 1.0× 146 0.7× 83 2.2k
Charlie Cao United States 13 391 1.1× 257 1.1× 33 0.2× 321 1.6× 43 0.2× 25 1.4k
Shubham Misra India 19 114 0.3× 259 1.1× 162 0.8× 281 1.4× 22 0.1× 83 1.2k
Zonggui Wu China 21 435 1.2× 174 0.8× 50 0.2× 625 3.1× 115 0.6× 67 1.9k
Omer Iqbal United States 19 442 1.2× 99 0.4× 39 0.2× 176 0.9× 27 0.1× 161 1.5k
Sharma Prabhakar United States 16 239 0.6× 283 1.2× 31 0.2× 488 2.4× 63 0.3× 37 1.9k

Countries citing papers authored by Hazem Elewa

Since Specialization
Citations

This map shows the geographic impact of Hazem Elewa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hazem Elewa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hazem Elewa more than expected).

Fields of papers citing papers by Hazem Elewa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hazem Elewa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hazem Elewa. The network helps show where Hazem Elewa may publish in the future.

Co-authorship network of co-authors of Hazem Elewa

This figure shows the co-authorship network connecting the top 25 collaborators of Hazem Elewa. A scholar is included among the top collaborators of Hazem Elewa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hazem Elewa. Hazem Elewa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yusuff, Kazeem B., et al.. (2025). Association between CYP2C19 polymorphism and proton pump inhibitors adverse drug reactions: a narrative review. Frontiers in Pharmacology. 16. 1523399–1523399.
2.
Elshafei, Mohamed Nabil, et al.. (2025). Direct oral anticoagulants versus warfarin for venous thromboembolism prophylaxis in nephrotic syndrome patients: a retrospective study. Thrombosis Journal. 23(1). 9–9. 1 indexed citations
3.
Saad, Mohamed, et al.. (2024). Accuracy of an internationally validated genetic-guided warfarin dosing algorithm compared to a clinical algorithm in an Arab population. Current Problems in Cardiology. 49(12). 102865–102865. 2 indexed citations
4.
Abdellatif, Rania, Radja Badji, Wadha Al‐Muftah, et al.. (2024). QPGx‐CARES: Qatar pharmacogenetics clinical applications and research enhancement strategies. Clinical and Translational Science. 17(6). e13800–e13800. 4 indexed citations
5.
6.
7.
8.
Awaisu, Ahmed, et al.. (2024). Evaluating the appropriateness and the factors associated with sodium-glucose co-transporter 2 inhibitors prescribing in a Middle Eastern country: a cross-sectional study. International Journal of Clinical Pharmacy. 47(2). 314–324. 1 indexed citations
9.
SALEM, M. R., et al.. (2023). Warfarin‐Rifampin‐Gene (WARIF‐G) Interaction: A Retrospective, Genetic, Case–Control Study. Clinical Pharmacology & Therapeutics. 113(5). 1150–1159. 2 indexed citations
10.
Rachid, Ousama, et al.. (2023). Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data. European Journal of Clinical Pharmacology. 79(12). 1675–1685. 2 indexed citations
11.
Elewa, Hazem, et al.. (2022). Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. International Journal of Clinical Pharmacy. 44(3). 599–607. 13 indexed citations
12.
Elewa, Hazem, et al.. (2022). Cost-Benefit Analysis of Genotype-Guided Interruption Days in Warfarin Pre-Procedural Management. Current Problems in Cardiology. 48(6). 101128–101128. 3 indexed citations
13.
Awaisu, Ahmed, et al.. (2022). A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country. International Journal of Clinical Pharmacy. 44(6). 1342–1350. 7 indexed citations
14.
15.
AlMukdad, Sawsan, Hazem Elewa, & Daoud Al‐Badriyeh. (2020). Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics. 25(3). 201–211. 23 indexed citations
16.
Elewa, Hazem, et al.. (2020). Anticoagulation clinic drive-up service during COVID-19 pandemic in Qatar. Journal of Thrombosis and Thrombolysis. 51(2). 297–300. 9 indexed citations
17.
Nader, Ahmed, et al.. (2019). Clinical and Pharmacokinetic Outcomes of Peak–Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial. European Journal of Drug Metabolism and Pharmacokinetics. 44(5). 639–652. 36 indexed citations
18.
Elewa, Hazem & Kyle John Wilby. (2017). A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications. European Journal of Drug Metabolism and Pharmacokinetics. 42(5). 745–756. 23 indexed citations
19.
Elewa, Hazem, et al.. (2017). Trends in oral anticoagulant use in Qatar: a 5-year experience. Journal of Thrombosis and Thrombolysis. 43(3). 411–416. 27 indexed citations
20.
Elewa, Hazem, et al.. (2013). Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. Journal of Thrombosis and Thrombolysis. 38(1). 115–120. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael J. Fossler Breakdown of academic impact, for papers by Célia Maria Cássaro Strunz Breakdown of academic impact, for papers by Joshua Goldberg Breakdown of academic impact, for papers by Zhi Liu Breakdown of academic impact, for papers by Shashank Rohatagi Breakdown of academic impact, for papers by Charlie Cao Breakdown of academic impact, for papers by Shubham Misra Breakdown of academic impact, for papers by Zonggui Wu Breakdown of academic impact, for papers by Omer Iqbal Breakdown of academic impact, for papers by Sharma Prabhakar
Rankless by CCL
2026